EuropeanRegulatory GateUpdated daily
European funding rounds in hardware and deep tech, new funds and public programmes, open calls, and the EU rules that change how founders raise capital — each with a short note on why it matters and a link to the source.
23 items
Oxford spin-out Alethio Therapeutics closed an oversubscribed €80.46 million Series A to advance targeted therapies for blood cancer, co-led by Sofinnova Partners and RA Capital. It highlights strong late-stage biotech investor appetite in Europe for deep-tech drug development.
Tech.eu reports on Europe's 10 most-funded healthtech companies in H1 2026, noting large rounds in biotech, medical devices and AI-powered healthcare with the UK leading investment. This market data helps founders and investors benchmark where healthtech capital is flowing in Europe.
Copenhagen-based Biograil raised €20 million to develop an oral device for delivering therapeutics that normally require injection. The round was backed by Verve Ventures, Megatrend Invest and HTGF's Opportunity growth fund, giving the medtech company fresh capital to advance its drug-delivery device.
UK-based human cell programming company bit.bio closed a $25 million Series D to expand its portfolio of human cell models for pharma and biotech customers. The funding supports a deep-tech biotech platform relevant to founders building cell-based technologies.
Biotech company Vitroscope raised $7 million, including a $5 million seed round, to develop perfusion platforms that turn living human tissue into drug discovery data. This is a deep-tech biotech raise relevant to founders building lab hardware and biological platforms.
Biotech company ALLOX raised $10.5 million in a seed round led by Asabys to expand its drug discovery platform and development programmes. Relevant for biotech founders as it shows seed-stage capital continuing to flow into European drug discovery tech.
Danish biotech Samplix announced a €25 million first close of a financing round, combining €3 million in new capital and €22 million in convertible bonds, to scale its droplet microfluidics antibody discovery platform. The deal shows continued investor confidence in European deeptech biotech infrastructure companies.
Swiss tech-bio firm Atlas Bio launched from stealth with $12.5 million in combined pre-seed and seed funding led by Creandum and First Momentum Ventures to reduce drug development failure rates and move beyond animal testing. It's a European biotech deep-tech round relevant to medtech and life-science founders.
Finnish insect-protein company Volare opened its first 10,000 m² industrial factory in Pori and secured €7.1M to scale production across Europe. This is a concrete example of deep-tech/cleantech hardware scaling financing relevant to physical-product founders.
German warm-chain logistics company Cellbox Solutions closed a €5 million Series A to expand its technology for transporting sensitive biological materials. It highlights ongoing funding for physical infrastructure supporting biotech and medtech supply chains.
Basel-based biotech Nouscom closed an oversubscribed €120 million Series D financing co-led by M Ventures and Revelation Partners to advance its neoantigen-based cancer immunotherapy. This is a sizeable late-stage biotech round relevant for deep-tech founders and investors tracking European clinical-stage financings.
Oxford spin-out OMass Therapeutics raised an oversubscribed €275 million Series C led by Bain Capital Life Sciences, Forbion and Novo Holdings to advance small-molecule therapies. It signals continued large-scale biotech investor appetite in the UK, relevant for deep-tech founders benchmarking round sizes.
UK biopharma Microbiotica announced the first close of a €42 million Series C led by British Business Bank with participation from Tencent, IP Group and others to develop precision microbiome medicines. Relevant as another European biotech growth round for benchmarking investor terms.
Milan's Panakès Partners launched an €8.5 million investment vehicle funded by Lombardia Venture STEP, the Lombardy Region's fund of funds, to back life sciences, MedTech and BioTech companies. This creates a new regional capital source for European medtech and biotech founders seeking early-stage investment.
Cambridge-based Undecimal Bio, a spin-out from Eleven Therapeutics, raised a €16 million seed round co-led by 4BIO Capital and IQ Capital to develop its AI-enabled DELiveri platform for targeted RNA medicines beyond the liver. This is a European biotech deep-tech round relevant to medtech-focused founders and investors.
Ghent-based SpectaCell, a spin-out from imec, VIB and Ghent University, raised €6 million in Seed funding led by imec.xpand to advance its cell analysis platform for immunotherapy development. It's a fresh example of European deep-tech biotech spin-outs attracting early institutional backing.
Paris-based Rivercell emerged from stealth with a €22m seed round led by HV, with HCVC, Alven and Bpifrance Digital Venture participating, to build AI-powered drug discovery infrastructure. It builds proprietary cell-response data and a predictive biological world model, relevant for deep-tech biotech founders seeking similar seed capital.
French foodtech Edonia raised €15 million to scale production of microalgae-based protein as a meat alternative. As a physical-product deep-tech company building novel bioprocessing, this shows continued investor interest in alt-protein manufacturing in Europe.
Paris-based WhiteLab Genomics raised a €23.2 million Series B led by AVP to accelerate its AI-driven genomic medicine design platform. As a biotech company building deep-tech drug-design tools, this is directly relevant to deep-tech founders raising capital in Europe.
Danish clinical-stage biopharma Breye Therapeutics closed an oversubscribed €67.5 million Series A to advance oral therapies for early retinal disease treatment, co-led by Mission BioCapital and Novo Holdings. It's a sizeable European medtech/biotech raise relevant to founders and investors tracking deep-tech healthcare funding.
Items are selected and summarised automatically from public sources once a day. The summary is ours; the facts belong to the linked source — check it before acting. This is market information, not investment or legal advice.